'Unprecedented' Responses to Neoadjuvant Tx in dMMR Colon Cancer

An 'innovative' study of short-course nivolumab plus ipilimumab prior to resection of MMR-deficient colon cancer has achieved 'unprecedented' pathologic responses, with no recurrences.

Related Keywords

Paris ,France General ,France ,Netherlands ,United Kingdom ,Valencia ,Carabobo ,Venezuela ,Spain ,London ,City Of ,Amsterdam ,Noord Holland ,James Larkin ,Myriam Chalabi ,Netherlands Cancer Institute ,European Society For Medical Oncology ,University Of Valencia ,European Society ,Medical Oncology ,Annuak Meeting ,New Results ,Royal Marsden ,Colorectal Cancer ,Cancer ,Alignant Neoplasia ,Arcinoma ,Colon Cancer ,Alignant Colon Neoplasm ,Tumor ,Chemotherapy ,Malignant Rectal Neoplasm ,Rectal Cancer ,Ancer Rectal ,Surgery ,Biologic Therapy ,Biopsy ,Immunotherapy ,Metastasis ,Colonoscopy ,Neoadjuvant ,Presection ,Disease Recurrence ,